Investigational drug · Phase 3
Lepodisiran
Also called: LY3819469
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Lepodisiran"
First trial start
2024
Mar 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lepodisiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atherosclerosis
- Cardiovascular Diseases
- Lipoprotein(a)
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Elevated Lp(a)
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Lepodisiran" as an intervention, largest first.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06292013 · 17,300 participants (planned) · Start Mar 5, 2024 · Primary completion Mar 2029
Drug: Lepodisiran Sodium; Placebo · For: Atherosclerotic Cardiovascular Disease (ASCVD); Elevated Lp(a)
Sites: Birmingham, Alabama; Daphne, Alabama; Dothan, Alabama · 928 sites in all
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High RiskPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07613294 · 252 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 2029
Drug: Lepodisiran; Placebo · For: Atherosclerosis; Cardiovascular Diseases; Lipoprotein(a)
Sites: La Jolla, California; Northridge, California; Torrance, California · 57 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07914738 · 66 participants (planned) · Start Nov 2, 2026 · Primary completion Mar 2027
Drug: LY3819469 · For: Lipoprotein(a)
Sites: Singapore, Singapore
Eli Lilly and CompanyEli Lilly (LLY)
NCT06916078 · 30 participants · Start Apr 23, 2025 · Primary completion Jul 13, 2026
Drug: Lepodisiran · For: Liver Dysfunction; Healthy
Sites: Miami, Florida; Orlando, Florida; San Antonio, Texas · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- RNA-Targeted Therapeutics in Cardiovascular Risk Reduction: From Gene Silencing to Precision Cardiology.
Karim A, Binte Imran S, Yousuf YM, et al. · Cardiol Rev 2026
- Nucleic acid-based and small-molecule therapies for lipoprotein(a) lowering: what the trials teach us and what they do not.
Yamaji T, Barkas F, Ray KK · Expert Opin Emerg Drugs 2026
- Pelacarsen and Lp(a)HORIZON: Interpreting the disconnect between lipoprotein(a) lowering and cardiovascular outcomes.
Sabouret P, Giamundo DM, Asher E, et al. · Am J Med 2026
- RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms.
Parcha V, Bittner VA · Curr Atheroscler Rep 2026
- Novel pharmacological targets for the treatment of aortic stenosis.
Anchouche K, Small AM, Thanassoulis G · Eur Heart J Valvular Struct Heart Dis 2026
- Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications.
Acierno C, D'Ardes D, Boccatonda A, et al. · J Cardiovasc Pharmacol 2026
Also in development for Atherosclerosis
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- YN001Phase 22 trials
Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.